EyeWorld Weekly, April 5, 2024 – EyeWorld
➤ One-year data from first-in-human drug eluting IOL ➤ Company begins two Phase 2 studies for glaucoma treatment ➤ First patient dosed in allogenic cell therapy trial ➤ Company outlines resubmission plan for reproxalap NDA ➤ Safety information for the upcoming solar eclipse ➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting ➤ Complimentary access to video journal ➤ ASCRS news and events